U.S. Government Orders Another 2.5 Million Doses of Monkeypox Vaccines from Bavarian Nordic

COPENHAGEN, Denmark, July 15, 2022 – Bavarian Nordic A/S (OMX:BAVA) announced today that the U.S. Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, has ordered an additional 2.5 million doses of liquid-frozen JYNNEOS^®, a non-replicating smallpox vaccine and the only FDA-approved vaccine against monkeypox.